PM generates numerous questions and concerns either in terms of ethics, human rights, financing and other perspectives, addressing:
What progress has been made so far bringing PM technologies to the market?
How to overcome clinical trials challenges with PM?
Is there any evidence of more efficiency in health care by introducing PM approaches? Are we morally obligated to implement PM innovations?
What are the regulatory barriers to PM developments? What is the influence of patent law on PM innovations? PM and processing genomic data, what are the GDPR risks? What are the solutions to identified concerns?